Table 1.
Demographic and cancer-related characteristics of patients receiving TACE or TACE + EBRT for hepatocellular carcinoma
| Gender (F/M) | Race | Age | MELD | TBR (mg/dL) | Alb (g/dL) | INR | CPT score | No. lesions | Total size of lesions (cm) | |
|---|---|---|---|---|---|---|---|---|---|---|
| TACE | 9/28 | White, 29 | 58.3 (10.8) | 12.7 (3.4) | 2.2 (1.2) | 3.2 (0.5) | 1.4 (0.2) | 8 | 1 | 4.0 (1.6) |
| Black, 3 | (5–12) | (1–5) | ||||||||
| Asian, 3 | ||||||||||
| TACE + EBRT | 0/7 | White, 6 | 64.2 (9.1) | 9.4 | 1.0 (0.4) | 3.7 | 1.2 (0.2) | 5 | 1 | 13.4 |
| Black, 1 | (2.4) | (0.8) | (5–8) | (1–4) | (5.3) | |||||
Values are counts, mean (SD), or median (range).
Abbreviations: Alb = albumin; CPT = Child-Pugh-Turcotte; EBRT = conformal external beam radiation with concurrent capecitabine; INR = international normalized ratio; MELD = Model for End-stage Liver Disease; TACE = transarterial chemoembolization; TBR = total bilirubin.